Veracyte (NASDAQ:VCYT) versus GeneLink (OTCMKTS:GNLKQ) Financial Survey

Veracyte (NASDAQ:VCYT) and GeneLink (OTCMKTS:GNLKQ) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Profitability

This table compares Veracyte and GeneLink’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veracyte	-2.18%	3.02%	2.80%
GeneLink	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Veracyte and GeneLink, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1	1	7	0	2.67
GeneLink	0	0	0	0	0.00

Veracyte presently has a consensus target price of $41.13, indicating a potential upside of 2.81%. Given Veracyte’s stronger consensus rating and higher possible upside, equities analysts plainly believe Veracyte is more favorable than GeneLink.

Volatility and Risk

Veracyte has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Comparatively, GeneLink has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500.

Earnings & Valuation

This table compares Veracyte and GeneLink”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$425.33 million	7.29	-$74.40 million	($0.15)	-266.67
GeneLink	N/A	N/A	N/A	N/A	N/A

GeneLink has lower revenue, but higher earnings than Veracyte.

Summary

Veracyte beats GeneLink on 7 of the 8 factors compared between the two stocks.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

About GeneLink

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.